MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Protagonist Therapeutics Inc

Cerrado

SectorSanidad

48.15 2.86

Resumen

Variación precio

24h

Actual

Mínimo

46.31

Máximo

48.89

Métricas clave

By Trading Economics

Ingresos

165M

132M

Ventas

166M

171M

P/B

Media del Sector

11.433

63.778

BPA

1.98

Margen de beneficios

77.166

Empleados

126

EBITDA

168M

127M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+44.62% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

791M

3B

Apertura anterior

45.29

Cierre anterior

48.15

Noticias sobre sentimiento de mercado

By Acuity

20%

80%

41 / 386 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Protagonist Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

10 mar 2025, 13:59 UTC

Principales Movimientos del Mercado

Protagonist Therapeutics Shares Rise After Positive Trial Data for Icotronkinra

Comparación entre iguales

Cambio de precio

Protagonist Therapeutics Inc previsión

Precio Objetivo

By TipRanks

44.62% repunte

Estimación a 12 Meses

Media 67.8 USD  44.62%

Máximo 82 USD

Mínimo 38 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Protagonist Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

N/A / 48.795Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

41 / 386 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.